Edition:
United States

Cumberland Pharmaceuticals Inc (CPIX.OQ)

CPIX.OQ on NASDAQ Stock Exchange Global Select Market

6.86USD
12:55pm EST
Change (% chg)

$-0.04 (-0.58%)
Prev Close
$6.90
Open
$6.91
Day's High
$6.91
Day's Low
$6.81
Volume
1,534
Avg. Vol
3,888
52-wk High
$7.95
52-wk Low
$5.30

Latest Key Developments (Source: Significant Developments)

Cumberland Pharmaceuticals Inc files for mixed shelf of up to $100 million
Tuesday, 7 Nov 2017 05:40pm EST 

Nov 7 (Reuters) - Cumberland Pharmaceuticals Inc ::Cumberland Pharmaceuticals Inc files for mixed shelf of up to $100 million .  Full Article

Cumberland Pharmaceutical reports Q3 loss per share $0.05
Tuesday, 7 Nov 2017 04:05pm EST 

Nov 7 (Reuters) - Cumberland Pharmaceuticals Inc :Cumberland Pharmaceutical reports 27% revenue growth in the third quarter.Q3 adjusted earnings per share $0.01.Q3 revenue rose 27 percent to $11.2 million.Q3 loss per share $0.05.  Full Article

Cumberland Pharmaceuticals launches promotion of Totect in U.S. for emergency oncology intervention
Monday, 25 Sep 2017 08:00am EDT 

Sept 25 (Reuters) - Clinigen Group Plc :Cumberland Pharmaceuticals launches promotion of Totect® in the U.S. for emergency oncology intervention.Cumberland Pharmaceuticals Inc - ‍announced promotional launch of totect (dexrazoxane hydrochloride), in U.S.​.  Full Article

Cumberland Pharmaceuticals Q2 adjusted loss per share $0.05
Tuesday, 8 Aug 2017 04:05pm EDT 

Aug 8 (Reuters) - Cumberland Pharmaceuticals Inc :Cumberland Pharmaceutical reports double digit revenue growth for the fourth consecutive quarter.Q2 adjusted loss per share $0.05.Q2 loss per share $0.32.Q2 revenue rose 17 percent to $8.7 million.Cumberland Pharmaceuticals - ‍new co-promotion agreement for Kristalose added; at June 30, had $49.0 million in cash and marketable securities, including approximately $34.6 million in cash and equivalents​.  Full Article

Cumberland Pharmaceuticals begin U.S. shipments of dexrazoxane for oncology patient support
Monday, 31 Jul 2017 08:15am EDT 

July 31 (Reuters) - Cumberland Pharmaceuticals Inc :Cumberland Pharmaceuticals begin U.S. shipments of dexrazoxane for oncology patient support.Cumberland Pharmaceuticals Inc - under terms of agreement, Cumberland is managing all marketing, promotion, and distribution of Totect in U.S..Cumberland Pharmaceuticals Inc - will begin distributing dexrazoxane, sold under brand name Totect, to U.S. wholesalers.  Full Article

Stonepine Capital Management reports 6.8 percent passive stake in Cumberland Pharmaceuticals
Friday, 19 May 2017 04:47pm EDT 

May 19 (Reuters) - Cumberland Pharmaceuticals Inc :Stonepine Capital Management Llc reports 6.8 percent passive stake in Cumberland Pharmaceuticals Inc as of May 9 - SEC filing.  Full Article

Cumberland Pharmaceuticals reports q1 adjusted EPS $0.02
Monday, 15 May 2017 04:05pm EDT 

May 15 (Reuters) - Cumberland Pharmaceuticals Inc :Cumberland pharmaceuticals reports revenue growth of 25% in first quarter 2017.Q1 revenue $9.6 million versus $7.7 million.Q1 adjusted earnings per share $0.02.Says for three months ended march 31, 2017, net revenues were $9.6 million, compared to $7.7 million.Qtrly loss per share attributable to common shareholders $0.08.  Full Article

Cumberland Pharmaceuticals entered into a co-promotion partnership with Poly Pharmaceuticals for Kristalose within U.S.
Wednesday, 26 Apr 2017 08:00am EDT 

April 26 (Reuters) - Cumberland Pharmaceuticals Inc :Cumberland Pharmaceuticals Inc - Entered into a co-promotion partnership with Poly Pharmaceuticals Inc for Kristalose within United States.Cumberland Pharmaceuticals- Under multi-year partnership terms, co to provide payments to Poly based on incremental prescriptions generated by its sales organization.  Full Article

Cumberland Pharmaceuticals Q4 revenue rose 13 pct to $9.1 mln
Tuesday, 7 Mar 2017 04:15pm EST 

Cumberland Pharmaceuticals Inc : Cumberland Pharmaceuticals Inc - reports FY 2016 adjusted earnings $0.11 per share . Cumberland Pharmaceuticals reports fourth quarter and full year 2016 financial results . Q4 revenue rose 13 percent to $9.1 million .Qtrly loss per share attributable to common shareholders $0.05.  Full Article

Cumberland defeats Mylan appeal in Acetadote patent case
Thursday, 26 Jan 2017 09:31am EST 

U.S. Appeals Court Rules In Favor Of Cumberland Pharmaceuticals : In patent dispute with mylan related to acetadote formulation-ruling . Federal circuit court of appeals upholds lower court ruling against mylan . Cumberland had accused mylan of patent infringement related to its antidote for overdoses of acetaminophen . Mylan had stiplulated to infringement, but asserted that cumberland's claims were invalid; lower court had disagreed with mylan on that point Further company coverage: [CPIX.O] [MYL.O].  Full Article

BRIEF-Cumberland Pharma Says Data Demonstrates Amifostine Reduces Gastro-Intestinal Toxicity For Multiple Myeloma Patients

* CUMBERLAND PHARMACEUTICALS INC - NEWLY PUBLISHED DATA DEMONSTRATES AMIFOSTINE REDUCES GASTRO-INTESTINAL TOXICITY FOR MULTIPLE MYELOMA PATIENTS Source text for Eikon: Further company coverage: